| Přispěvatelé: |
Mengelo?lu, F.Z., Abant Izzet Baysal University, Faculty of Mediane, Department of Medical Microbiology, 14280 Bolu, Turkey -- Taş, T., Abant Izzet Baysal University, Faculty of Mediane, Department of Medical Microbiology, 14280 Bolu, Turkey -- Koço?lu, E., Abant Izzet Baysal University, Faculty of Mediane, Department of Medical Microbiology, 14280 Bolu, Turkey -- Çopur Çiçek, A., Recep Tayyip Erdogan University, Faculty of Medicine, Department of Medical Microbiology, Rize, Turkey -- Yanik, K., Ondokuz Mayis University, Faculty of Medicine, Department of Medical Microbiology, Samsun, Turkey -- Güneş, H., Namik Kemal University, Faculty of Medicine, Department of Medical Microbiology, Tekirdag, Turkey -- Çiftci, I.H., Sakarya University, Faculty of Medicine, Department of Medical Microbiology, Sakarya, Turkey -- Durmaz, S., Osmaniye State Hospital, Microbiology Laboratory, Osmaniye, Turkey -- Bucak, Ö., Abant Izzet Baysal University, Faculty of Mediane, Department of Medical Microbiology, 14280 Bolu, Turkey -- Güçkan, R., Amasya University, Serafeddin Sabuncuoglu Educational and Research Hospital, Microbiology Laboratory, Amasya, Turkey -- Terzi, H.A., Sakarya University, Faculty of Medicine, Department of Medical Microbiology, Sakarya, Turkey -- Yavuz, M.Z., Abant Izzet Baysal University, Faculty of Medicine, Department of Medical Pharmacology, Bolu, Turkey |
| Popis: |
PubMed ID: 24237436 Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging pathogen that cause severe community-and hospital-acquired infections. Studies continue on searching alternatives due to the limited number of therapeutic options in MRSA infections. Ceftaroline is a wide-spectrum new generation cephalosporin which has been begun to be used in treatment of skin and respiratory tract infections caused by MRSA. The aim of this study was to investigate the in vitro activity of ceftaroline against MRSA strains isolated from various clinical specimens in microbiology laboratories of seven hospitals located at different provinces (Bolu, Samsun, Rize, Tekirdag, Sakarya, Amasya, Osmaniye) of Turkey. A total of 192 MRSA isolates (89 skin/wound/abscess, 38 blood, 36 respiratory tract, 29 urine/sterile body fluids/catheter) were included in the study, and ceftaroline susceptibilities of the strains were detected by broth microdilution method. MIC values of 181 (94.3%) isolates were determined as ? 1 ?g/ml meaning of susceptible according to the criteria of CLSI, and MIC values of 11 (5.7%) isolates were found as 2 ?g/mL indicating intermediate susceptibility. The range of MIC values of the isolates was found between 0.25-2 ?g/ml. The rates of intermediate isolates have varied between 0-12.5% from the participating centers. MIC50 and MIC90 values of all the isolates were determined as 0.5 ?g/ml and 1 ?g/ml, respectively. No significant differences were found between the centers in terms of mean MIC values (p> 0.05). MIC50 and MIC90 values in Samsun and Bolu isolates were found to be the same with the whole group, however, MIC 50 and MIC90 were 0.5 ?g/ml and 0.5 ?g/ml in Amasya isolates and 1 ?g/ml and 1 ?g/ml in Rize, Tekirdag, Osmaniye and Sakarya isolates, respectively. When evaluating MIC50 and MIC90 values and isolation rates of intermediate strains according to the specimen types, there were no significant differences (p> 0.05). Susceptibility rates to ceftaroline and the distribution profiles of MIC values of the isolates obtained from seven centers of Turkey have been detected similar with the previous American and European reports. With this study, initial data on the activity of ceftaroline against MRSA were obtained from Turkey. These preliminary findings indicate that ceftaroline is effective even on Turkish isolates and can be a suitable treatment in cases requiring wide-spectrum antimicrobiotic use, however further large-scaled studies are needed. |
